Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 08:00 am ET
Good morning and welcome to Kala Pharmaceuticals' First Quarter 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.
Thank you, operator, and thank you all for participating in today's call. Joining me from the Company are: Mark Iwicki, Chairman, President and Chief Executive Officer; Todd Bazemore, Chief Operating Officer; Mary Reumuth, Chief Financial Officer; Kim Brazzell, Chief Medical Officer; and Hongming Chen, Chief Scientific Officer. Today's call is being webcast live. The webcast link can be found in the Investors and Media section of our website at www.kalarx.com.
During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today, which can also be found on our website.
On this call, we will make certain comments about Kala's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include observations associated with our commercialization of INVELTYS; statements regarding the regulatory and commercial plans for EYSUVIS, including the timing of the FDA review of our NDA; the sufficiency of our cash resources; and projected revenue. These statements are based on the beliefs and expectations of management as of this conference call. Our actual results may differ materially from our expectations. The Company undertakes no obligation to revise or update any statements to reflect events or circumstances after this conference call. Investors should carefully read the risks and uncertainties described in today's press release, as well as the risk factors, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statement included in the Company's quarterly report on Form 10-Q and other filings we make with the SEC. The Form 10-Q will be filed with the SEC later today and will be available on our website.
I will now turn the call over to Kala's CEO, Mark Iwicki.
Mark T. Iwicki
Thank you, Niranjan. Good morning, everyone, and thanks for joining us. Earlier today, we issued a press release detailing our first quarter 2020 financial results and recent business highlights.
Before speaking to our progress, I want to acknowledge the ongoing COVID-19 pandemic. These are challenging and uncertain times for all of us. In a matter of months, the way we live and conduct business has been significantly changed and many of us have experienced firsthand the social, economic and emotional burdens brought by COVID-19. Like all of you, we are deeply grateful to the doctors, nurses and other healthcare professionals on the front lines, and we are hopeful that ongoing efforts across the world will soon result in new therapies and vaccines to treat and prevent the further spread of COVID-19.